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The performance of the interferon gamma release assays (IGRAs) and tuberculin skin test (TST) was reviewed retrospectively in
patients with psoriasis, inﬂammatory musculoskeletal diseases, or miscellaneous inﬂammatory conditions. The study was carried
out over a 22-month period using 109 records of patients with psoriasis (n = 21), musculoskeletal disease (n = 74), or other
inﬂammatory conditions (n = 14). Forty-four (48%) of 109 patients were on immunosuppressive therapy and 38/109 (35%) on
systemic glucocorticoid therapy. The agreement between the IGRAs was substantial (κ = 0.71) whilst that between the IGRAs and
TSTwaslow(κ = 0.32).LogisticregressionmodelsrevealedthatIGRAsassociatedwithriskfactorsforlatenttuberculosisinfection
better than TST. TST was inﬂuenced by age, BCG vaccination, sex, and glucocorticoid therapy. We found that IGRAs performed
equally well with low level of indeterminate results (1-2%). IGRAs were superior to TST because the latter was inﬂuenced by
BCG-vaccination status and immunosuppressive therapy.
1.Introduction
Patients with latent tuberculosis infection (LTBI) have an
increased risk for activation of tuberculosis (TB) if they are
treated with cytostatic drugs or systemic corticosteroids [1].
The risk of LTBI reactivation is further increased by the
treatmentwithtumour-necrosis-factor-α-(TNFα-)blocking
agents [2] ,w h i c hh a v eb e e np r o v e nt ob ee ﬀective therapy
in autoimmune conditions such as rheumatoid arthritis
(RA), psoriasis and psoriasis arthritis (PsA), and ankylosing
spondylitis. In RA patients the treatment with TNFα-
blocking agents causes a 2–4-fold increase in the risk of TB
[3]. In countries with a low incidence/prevalence of TB, this
occurrence of TB in RA is considered to derive mainly from
reactivation of LTBI. To prevent the reactivation, national
guidelines have been expressed for screening and treatment
of LTBI prior to starting anti-TNFα therapy [4–6].
Two commercial interferon-γ (IFNγ) release assays
(IGRAs), namely, T-SPOT.TB (Oxford Immunotec, Oxford,
UK) and QuantiFERON-TB Gold In-Tube (Cellestis Lim-
ited, Carnegie, Victoria, Australia), have been developed.
Both utilize the ability of sensitized T lymphocytes to release
IFNγ upon stimulation with synthetic peptides speciﬁc to2 International Journal of Rheumatology
Mycobacterium tuberculosis. These methods show superior
diagnostic accuracy in comparison to the tuberculin skin test
(TST) [7].
The present retrospective study aimed to investigate
associations between the risk factors for LTBI, vaccination
status, or prior immune suppression and the results of the
two commerciallyavailable IGRAs, which were appropriately
modiﬁed, and TST in patients with psoriasis and inﬂamma-
tory musculoskeletal diseases.
2.MaterialsandMethods
2.1. Patients. We analyzed the results of the 109 patients
treated at the Helsinki University Central Hospital between
February 2007 and December 2008 who were screened
for LTBI with IGRAs and with TST. All the IGRAs had
been carried out at HUSLAB, Helsinki University Central
Hospital,Helsinki,Finland.Wereviewedthemedicalrecords
and collected data on chest X-ray examinations, history of
exposure to Mycobacterium tuberculosis, ongoing use of glu-
cocorticoids, immunosuppressive drugs, and/or biologicals.
We divided patients into three categories according to their
diagnoses (Table 1). Group 1 comprised 21 (19.2%) patients
with psoriasis and psoriasis arthritis. Group 2 comprised
74 (67.9%) patients with inﬂammatory musculoskeletal
diseases. Group 3 consisted of 14 (12.8%) patients with
miscellaneous inﬂammatory conditions.
2.2. Ethics Statement. The study protocol was approved by
theEthicsCommitteeofHelsinkiandUusimaaHospitalDis-
trict Area.
2.3. Deﬁnitions
2.3.1. Partially Treated TB. Patients with a history of tuber-
culosis whose anti-tuberculosis therapy had not included a
three-drug regimen were considered to have had a partial
treatment.
2.3.2. Vaccination Status. Newborns were systematically vac-
cinated in maternity hospitals in Finland between 1950
and 2006. Accordingly, patients born in 1950 or later were
considered as vaccinated.
2.3.3. Chest X-Ray Suggestive of TB. Apical scar, primary
complex, ﬁbrosing pleural changes with/without calciﬁca-
tions, and ﬁbrotic parenchymal foci were the signs indicative
for LTBI.
2.4. IGRAs. IGRAs were performed according to the stan-
dardoperatingprocedures(SOPs)adoptedforbothmethods
in our laboratory. For each test we developed an internal
quality control sample, that is, the preparation resembling
the actual clinical sample that was divided into aliquots and
assayed regularly.
The commercial T-SPOT.TB was modiﬁed and validated
asearlierdescribed[8].Brieﬂy,themodiﬁcationsinclude:the
following (i) results are expressed as a number of reactive
spots/106 lymphocytes, and the lymphocyte count from
isolated PBMC preparation is calculated with an automated
hematologic analyzer (Advia 60, Bayer, Germany) for cell
quantiﬁcation and purity assessment; (ii) an additional
positive control, that is puriﬁed protein derivative (PPD)
(Statens Serum Institut, Copenhagen, Denmark) that was
used with each sample; (iii) the analysis is performed in
duplicates.
The B-TbIFNg is a modiﬁed version of the
QuantiFERON-TB Gold In-Tube [8]. The major
modiﬁcation was the substitution of the original enzyme
immunoassay (EIA) for IFN-γ (Cellestis Limited, Carnegie,
Victoria, Australia) by that of PeliKine Compact human EIA
(Sanquin, Amsterdam, The Netherlands). The latter gave a
steeper calibration curve and ensured more accurate result
interpretation in the cutoﬀ zone [8].
2.4.1. The Cut-Oﬀs. Based on our imprecision study and
a pilot evaluation [8, 9], we used the following cut-oﬀs
for our routine: for the B-TbIFNg 0.35–0.5IU/mL and
for the Ly-TbSpot 25–50 reactive cells/106 lymphocytes.
However, to make the results comparable with other studies,
the calculations were based on the cut-oﬀs deﬁned by the
manufacturer, that is 0.35IU/mL and 25 reactive cells/106
lymphocytes, equal to 6 spots/well.
2.5. TST. TST was performed by properly trained operators
with 2 TU of puriﬁed protein derivative (PPD, RT23, Statens
Serum Institut, Copenhagen, Denmark) according to the
Mantoux technique on the surface of the forearm. The result
was recorded after 48–72h, and induration ≥10mm was
used as a positive result.
2.5.1. Statistical Analysis of the Data. In the absence of the
“goldstandard,”weevaluatedtheperformanceofLy-TbSpot,
B-TbIFNg, and TST and assessed the results according to
the presence of any risk factor for LTBI: history of active
tuberculosis, birth in an endemic country, or a history of a
close TB contact. Chest X-ray ﬁnding suggestive of a history
of TB was primarily considered as a risk factor but was
omitted from the index because (i) it was associated with
odds less than 1 for positive test results; (ii) when the chest
X-ray ﬁndings indicated LTBI, IGRA and TST were often not
requested by physicians.
The odds ratios for positive test results were calculated
with univariate logistic regression. We evaluated the results
in association with an attribution to a group that is, each
result was compared to all other results and to potential
confounding factorssuchasage,sex,BCG-vaccinationstatus
and medications. Covariates with signiﬁcance of P<0.1
in the univariate analyses and independent from each other
were included.
Cohen’s kappa statistic was used to assess the agreement
between the tests. We used logistic regression for the analysis
of factors contributing to concordance and discordance
between tests pairwise. All P- v a l u e sw e r et w os i d e d .
3. Results
3.1. Characteristics of Patients. Table 1 summarizes the char-
acteristics of the study cohort. The majority of the par-
ticipants were Finnishborn, 12 (11%) had a history of TBInternational Journal of Rheumatology 3
Table 1: Patient characteristics.
Variable Total
(n = 109)
Group∗
(n = 21)
Group 2†
(n = 74)
Group 3‡
(n = 14)
Age, mean years 57.5 51 58.7 60.9
Quartiles 25–75% 48.5–68.4 41.4–57.4 48.5–70.3 50.8–66
Sex
Female, n (%) 65 (60) 8 (38) 49 (66) 8 (57)
Born in TB-endemic country§
Yes, n (%) 12 (11) 0 (0) 9 (12) 3 (21)
Contact with TB
Yes, n (%) 12 (11) 0 (0) 11 (15) 3 (21)
Previous TB-history
No, n (%) 97 (89) 19 (90) 64 (86) 14 (100)
Full treatment, n(%) 4 (4) 1 (5) 3 (4) 0 (0)
Partially treated, n (%) 8 (7) 1 (5) 7 (9) 0 (0)
Positive chest X-ray||
Yes, n (%) 8 (7) 0 (0) 7 (9) 1 (7)
BCG vaccination
Yes, n (%) 46 (42) 16 (76) 27 (36) 3 (21)
Treatment
Corticosteroids, n (%) 38 (35) 1 (5) 31 (42) 6 (43)
Cytostatics, n (%) 48 (44) 9 (43) 35 (47) 4 (29)
Biological, n (%) 6 (6) 4 (19) 2 (3) 0 (0)
∗Psoriasis.
†Inﬂammatory musculoskeletal diseases: rheumatoid arthritis 38, ankylosing spondylitis 11, vasculitis 7, seronegative polyarthritis 6, oligoarthritis 4, myositis
3, juvenile idiopathic arthritis 2, chronic reactive arthritis 1, systemic lupus erythematosus 1, spondyloarthritis 1.
‡Miscellaneous inﬂammatory conditions: bronchial asthma 2, diabetes/renal transplantation 1, chronic alcholism 1, hypersedimentation 1, lung infection
(mycobacterium avium-intracellulare) 1, Poncet’s disease 1, Polycystic disease/renal transplantation 1, renal dysfunction 1, tubulointerstitial nephritis 1,
pleuritis, lung ﬁbrosis 1, lymphoma 1, universal arteriosclerosis 1, spinal pseudotumor 1.
§Cambodia, Chile, Cuba, Estonia (n = 2), Morocco (n = 2), Poland, Somalia (n = 2), Turkey, Ukraine.
||Available in 99 patients.
contacts, and 12 (11%) had a history of TB. Eight of 99 (8%)
patients had radiological evidence for LTBI, and less than a
half of the participants had received BCG vaccination (n =
46 (42%)). Six (6%) patients were on anti-TNFα blocking
therapy. Ly-TbSpot test was performed in 98, B-TbIFNg in
71, and TST in 80 patients, respectively (Table 2). 49 patients
had all three tests performed.
3.2. The IGRAs. The risk factor analysis revealed that those
being born in endemic countryor having a history of contact
or previous TB had higher odds for positive Ly-TbSpot
(OR 2.9; P<0.05, Table 3) and B-TbIFNg (OR 5.0; P<
0.01, Table 4). Patient group or medication did not have
signiﬁcant eﬀects on IGRA results (Tables 3 and 4). Females
had lower odds for positive Ly-TbSpot (OR 0.4, P<0.05)
than men, also in multivariate analysis.
3.3. TST. Age correlated negatively with a positive TST reac-
tion, OR 0.95 (P<0.01), that is patients with negative TST
were older (mean 65.9 years) than those with positive TST
(52.4 years). Also BCG vaccination correlated moderately
with TST (10mm, P<0.1). Females had lower odds for
positive TST, OR 0.2 (P<0.01), than men. Group 3 had
lower odds for positive test results compared with the other
groups, although the number of TST performedwaslower in
this group (Table 5).
We found an association between TST positivity and
birth in TB-endemic country, sex, and inclusion in group 3.
As age and BCG vaccination status were not independent,
theywereincludedascovariatesseparately,bothshowingsig-
niﬁcant association with test results. Ongoing glucocorticoid
therapy had an eﬀect on TST, OR 0.3 (P<0.05), but this
eﬀect was not conﬁrmed in multivariate analysis (data not
shown).
3.4. Agreement between the Tests. In the pairwise analysis
(Table 6), we found no signiﬁcant factors explaining the
disagreement between the IGRA results. The LTBI risk
factors were associated with concomitant positivity in both
IGRA tests.
BCG vaccination was associated with the TST +ve/IGRA
−ve discrepancy. Age had a bidirectional inﬂuence on the
test results. Younger persons tended to be in the TST
+ve/Ly-TbSpot−ve discrepancy group, whilst advanced age
was associated with TST −ve/Ly-TbSpot +ve discrepancy.
Young age was associated both with TST +ve/B-TbIFNg4 International Journal of Rheumatology
Table 2: Number of tests performed to the study population.
Group 1
n = 21
Group 2
n = 74
Group 3
n = 14
Ly-TbSpot, n (%)
Not done 5 (23.8)∗ 5 (6.8) 1 (7.1)
Neg 12 (57.1) 46 (62.2) 9 (64.3)
Pos 4 (19.0) 22 (29.7) 3 (21.4)
Indeterminate 0 (0.0) 1 (1.4) 1 (7.1)
B-TbIFNγ, n (%)
Not done 2 (9.5)† 28 (37.8) 7 (50.0)∗
Neg 17 (81.0) 34 (45.9) 5 (35.7)
Pos 2 (9.5) 11 (14.9) 2 (14.3)
Indeterminate 0 (0.0) 1 (1.4) 0 (0.0)
TST cut oﬀ 10mm, n (%)
Not done 8 (38.1) 12 (16.2)† 9 (64.3)∗
Neg 4 (19.0) 28 (37.8) 4 (28.6)
Pos 9 (42.9) 34 (45.9) 1 (7.1)
∗Higher proportion of missing test results, compared with the two other patient groups, P<0.05.
†Lower proportion of missing test results, compared with the two other patient groups, P<0.05.
Table 3: The univariate analysis of the TB risk factors with a positive outcome of the Ly-TbSpot test.
Variable All patients
n = 109
Ly-TbSpot
n = 98 Odds ratio Signiﬁcance
Positive n = 29 (29.6) (95% CI) P<
Age, mean (test neg. mean) 57.5 56.8 (59.4) 1.0 (0.98–1.05) 0.4
Sex, female, n (%) 65 (59.6) 12 (41.4) 0.4 (0.1–0.9) 0.02
BCG vaccination, n (%) 46 (42.2) 8 (27.6) 0.4 (0.2–1.1) 0.09
Born in TB-endemic country, n (%) 12 (11.0) 6 (20.7) 3.3 (0.9–12.0) 0.07
Contact with TB, n (%) 15 (13.8) 5 (17.2) 1.4 (0.4–4.6) 0.6
Previous TB-history, n (%) 12 (11.0) 5 (17.2) 2.2 (0.6–7.8) 0.2
Any risk factor for LTBI, n (%) 33 (30.3) 14 (48.3) 2.9 (1.1–7.1) 0.03
Positive chest X-ray, n (%) 8 (7.3) 1 (4.0) 0.5 (0.1–4.4) 0.5
Group 1, n (%) 21 (19.3) 4 (25.0) 0.8 (0.2–2.6) 0.7
Group 2, n (%) 71 (65.1) 22 (31.9) 1.2 (0.7–2.0) 0.4
Group 3, n (%) 17 (15.6) 3 (23.1) 0.8 (0.5–1.2) 0.3
Corticosteroids, n (%) 38 (34.9) 11 (37.9) 1.0 (0.4–2.5) 1.0
Cytostatic treatment, n (%) 48 (44.0) 14 (48.3) 1.1 (0.5–2.6) 0.9
Biological treatment, n (%) 6 (5.5) 1 (3.4) 0.5 (0.1–4.1) 0.5
−ve discrepancy and concomitant TST/B-TbIFNg positivity.
Male gender and corticosteroid medication were associated
with TST positivity.
The limitation of this analysis is the low number of
Ly-TbSpot −ve/B-TbIFNg +ve and TST −ve/B-TbIFNg +ve
discrepancy groups.
The IGRAs produced highly concordant results (κ =
0.71) (Table 6). On the contrary, TST showed poor concor-
dance with the IGRAs (κ = 0.24–0.32). When the concor-
dance of the tests was assessed for each group separately, the
conclusiondrawnforthewholecohortheldtruealsoforeach
group (data not shown).
3.5. Indeterminate Results. The rates of indeterminate results
were 2/98 (2%) and 1/71 (1.4%) for Ly-TbSpot and for B-
TbIFNg, respectively. As to the former, both patients had
lymphopenia. In one of them, although the B-TbIFNg test
was negative showing an acceptable PHA reactivity, we
doubted its validity because this method provides neither
visual assessment nor lymphocyte normalisation, as for
example, Ly-TbSpot. In one patient, the B-TbIFNg was
indeterminate due to nonsuﬃcient PHA reactivity but the
same sample tested in Ly-TbSpot was acceptable because the
reactivities both to PHA and PPD were suﬃcient.
4. Discussion
Here, we present ﬁndings that are not consistent with some
previous studies [10, 11]. We did not observe a severe
impairment with ongoing glucocorticoid or immunosup-
pressive antirheumatic therapy on the ex vivo function of
lymphocytes in IGRA tests. Indeed, in our practice the ratesInternational Journal of Rheumatology 5
Table 4: The univariate analysis of the TB risk factors with a positive outcome of the B-TbIFNg test.
Variable All patients
n = 109
B-TbINFγ
n = 71 Odds ratio Signiﬁcance
Positive n = 15 (21.1) (95% CI) P<
Age, mean (test neg. mean) 57.5 58.7 (58.8) 1.0 (0.96–1.04) 1
Sex, female, n (%) 65 (59.6) 7 (46.7) 0.6 (0.2–1.8) 0.4
BCG vaccination, n (%) 46 (42.2) 4 (26.7) 0.4 (0.1–1.5) 0.2
Born in TB-endemic
country, n (%) 12 (11.0) 3 (20.0) 2.6 (0.5–12.2) 0.3
Contact with TB, n (%) 15 (13.8) 4 (26.7) 3.0 (0.7–12.6) 0.2
Previous TB-history, n (%) 12 (11.0) 4 (26.7) 3.7 (0.9–16.1) 0.08
Any risk factor for LTBI, n
(%) 33 (30.3) 9 (60.0) 5.0 (1.5–16.6) 0.009
Positive chest X-ray, n(%) 8 (7.3) 1 (7.1) 0.9 (0.1–9.0) 0.9
Group 1, n (%) 21 (19.3) 2 (10.5) 0.4 (0.07–1.7) 0.2
Group 2, n (%) 71 (65.1) 11 (24.4) 1.3 (0.7–2.5) 0.4
Group 3, n (%) 17 (15.6) 2 (28.6) 1.2 (0.6–2.1) 0.6
Corticosteroids, n (%) 38 (34.9) 3 (20.0) 0.5 (0.1–2.1) 0.4
Cytostatic treatment, n (%) 48 (44.0) 6 (40.0) 1.0 (0.3–3.3) 1.0
Biological treatment, n (%) 6 (5.5) 0 (0) — 1.0
Table 5: The univariate analysis of the TB risk factors with a positive outcome for TST.
Variable All patients
n = 109
TST cut-oﬀ 10mm
n = 80 OR Signiﬁcance
Positive n = 44 (95% CI) P<
Age, mean (test neg. mean) 57.5 53.0 (62.4) 0.95 (0.92–0.99) 0.006
Sex, female, n (%) 65 (59.6) (47.7) 0.2 (0.06–0.5) 0.002
BCG vaccination, n (%) 46 (42.2) 23 (52.3) 2.4 (1.0–6.3) 0.06
Born in TB-endemic country, n
(%) 12 (11.0) 8 (18.2) 7.8 (0.9–65.5) 0.06
Contact with TB, n (%) 15 (13.8) 5 (11.4) 0.5 (0.2–1.8) 0.6
Previous TB history, n ( %) 12 (11.0) 6 (13.6) 0.8 (0.2–2.7) 0.7
Any risk factor for LTBI, n (%) 33 (30.3) 15 (34.1) 0.9 (0.4–2.3) 0.9
Positive chest X-ray, n (%) 8 (7.3) 2 (4.9) 0.5 (0.1–3.1) 0.5
Group 1, n (%) 21 (19.3) 9 (69.2) 2.1 (0.6–7.3) 0.3
Group 2, n (%) 71 (65.1) 34 (54.8) 1.0 (0.6–1.7) 1.0
Group 3, n (%) 17 (15.6) 1 (20.0) 0.5 (0.2–1.0) 0.06
Corticosteroids, n (%) 38 (34.9) 9 (20.5) 0.3 (0.1–0.9) 0.03
Cytostatic treatment, n (%) 48 (44.0) 24 (54.5) 1.9 (0.8–4.6) 0.2
Biological treatment, n (%) 6 (5.5) 2 (4.5) 0.5 (0.1–3.3) 0.5
of indeterminate results were very low and were mainly
attributed to lymphopenia. In our laboratory, EIA-based
methods performed equally well as the ELISPOT method,
although EIA-method measures only the bulk of excreted
interferon gamma and does not allow visual assessment of
the quality. The good performance may be partly attributed
to the EIA reagents from another manufacturer providing
a steeper calibration curve, which makes the reading and
interpretation more reproducible at the cut-oﬀ zone [8].
T h e r ea r es e v e r a ls t u d i e sw h e r et h eI G R A sh a v eb e e n
compared in rheumatic and psoriatic patients ([10–16]. As
reported [10–17]a n dr e v i e w e d[ 7, 18, 19]), the concordance
between IGRAs and TST in adults was poor. In accordance
with recent studies [10, 16], our results show good cor-
relation between the IGRAs. Similarly to Switzerland [12],
almost 100% of the Finnish population born after ﬁfties
is BCG vaccinated. We have found a negative association
between age and TST positivity. This goes hand in hand with
the positive association between BCG vaccination and TST
results. On the contrary, the IGRAs were not aﬀected by age
or BCG status. This ﬁnding corroborated results from other
studies [12, 13].6 International Journal of Rheumatology
Table 6: The agreement between IGRAs and TST with negative/negative as the reference category.
Negative Positive n Concordance Kappa
(std. Error)
Ly-TbSpot
B-TbIFNg Negative, n (%) 41 (64) 8 (13) 64 0.88 0.71 (0.09)
Positive, n (%) 0 (0) 15 (23)
Any risk factor 3.6
(1.06–12)
TST cut-oﬀ 10mm Negative, n (%) 28 (38) 5(7) 74 0.65 0.32 (0.10)
Age 1.14 (1.01–1.29)
Positive, n (%) 21 (28) 20 (27)
Age 0.94 (0.90–0.98)
Woman 0.22 (0.057–0.87) Woman 0.071
(0.017–0.30)
BCG 3.6 (1.11–12)
B-TbIFNγ
TST cut oﬀ 10mm Negative, n (%) 19 (37) 3 (6) 51 0.61 0.26 (0.11)
Positive, n (%) 17 (33) 12 (24)
Age 0.90 (0.85–0.97) Age 0.93 (0.87–0.99)
Woman 0.17 (0.035–0.78) Woman 0.13 (0.025–0.72)
BCG 4.7 (1.18–18)
Costeroids 0.15 (0.03–0.83) Corticosteroids 0.10 (0.01–0.94)
Our study has some limitations: the design was retro-
spective and the cohort was limited in patient numbers with
unequal sizes of the patient groups. Thus, the calculated
statistical parameters presented here should be regarded
with caution. Another limitation of the study was that the
interpretationofthechestX-rayﬁlmswasnotalwaysfocused
on ﬁnding the Ghon’s complex, the only objective indication
of a TB exposure. This makes the chest X-ray ﬁlm inferior
to the other risk factors studied. Our ﬁnding corroborates
the recent ﬁndings that the chest X-ray ﬁlm gives a low
yield in TB screening [10, 16, 20] and is a poor predictor
of LTBI, although often this component is included into
the diagnostic triad for LTBI. In our observation, calciﬁed
granuloma on the chest X-ray is not a precise correlate for
LTBI because it may not be sensitive enough to reveal the
lung tissue abnormalities in question.
Among all risk factors the strongest for a positive IGRA
outcome appeared to be a partially treated TB (OR 7.2 and
4.6 for EIA-based and ELISPOT-based techniques, resp.). Of
note, this risk factor did not emerge in the TST analysis
(OR 1.2: 95 CI% 0.2–12). Furthermore, birthplace outside
Finland(wheretheburdenwithenvironmentalmycobacteria
is often high) emerged as a trend for a positive TST result
whereasfortheIGRAsthisfactorwaslessstronglyassociated.
It is of note that our participants were heterogeneous in
relation to the factor of birthplace: only 5/12 persons were
born in highly endemic countries as deﬁned by WHO
[21]. Of the rest of the subjects, 7/12 were born in the
countries with a moderate and highly interregional variable
TB incidence, as in Estonia.
The correlation between partial TB treatment and a
positiveIGRAtestisexpected.Tapaninenetal.haveobserved
that even complete three-drug antituberculosis regimen
given decades ago may not lead to the complete attrition
of earlier sensitized lymphocytes that may recognize cognate
antigens upon new ex vivo stimulation [22]. For that reason
IGRAs should not be recommended as a follow-up method
to monitor treatment eﬃcacy.
The results of the present study encourage us to rec-
ommend EIA-based techniques throughout Finland and to
other areas, where the sample transportation is challenged
both by long distances and changes in temperature in the
north temperate zone. This method can be applied to LTBI
diagnostics in the majority of cases in whom systemic
biological drugs are indicated. IGRA-based methods are of
no doubt superior to TST because in contrast to TST, IGRAs
provide negative result that can be distinguished from a
false negative result due to immunological anergy, a feature
of extreme importance when testing immunosuppressed
patients. We are not in favour of simultaneous TST and
IGRA testing for the screening of LTBI in patients with
autoimmune conditions as suggested by Bartalesi et al. [23].
In their study only 4% of subjects were BCG vaccinated
which may lead to better agreement between the methods.
Moreover, our analysis showed that corticosteroid therapy
is negatively associated with a positive TST making thisInternational Journal of Rheumatology 7
method unreliable in patients with autoimmune disorders.
In case of lymphopenia, an ELISPOT-based method should
be preferred because the method allows puriﬁcation and
concentration of lymphocytes.
5. Conclusions
In the present study B-TbIFNg and Ly-TbSpot proved to be
methods of choice in evaluation of LTBI.
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